Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
387 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01697527 | Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies | active not recruiting | Phase 2 | 6 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05045027 | Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma | active not recruiting | Early Phase 1 | 36 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT06090643 | Implementation Research to Increase Colorectal Cancer Screening Rates Among Low Income and Ethnic Minority Groups | active not recruiting | N/A | 9,745 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT06376565 | Improving Colonoscopy Surveillance for Patients With High Risk Colon Polyps | recruiting | N/A | 1,680 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT03582475 | Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate | active not recruiting | Phase 1 | 15 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT02280161 | Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer | recruiting | — | 2,000 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT03672773 | Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer | active not recruiting | Phase 2 | 35 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT04553770 | Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | recruiting | Phase 2 | 88 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05558904 | An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer | recruiting | Phase 1 / Phase 2 | 60 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05978128 | Utilizing Advocates and Supporters to Increase Lung Cancer Screening Rates in Eligible Participants | recruiting | N/A | 800 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT06090903 | Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma | recruiting | N/A | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT03541850 | Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery | active not recruiting | Phase 2 | 92 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT05523700 | Value-based Integrated Recommendation Software Guiding Ovarian Cancer Treatment (VIRGO2)(VIRGO) | completed | N/A | 10 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT06059690 | Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells | recruiting | Phase 1 / Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Oct 8, 2025 | clinicaltrials |
| NCT01990196 | Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer | active not recruiting | Phase 2 | 45 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT02775292 | Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1(NYM) | completed | Phase 1 | 1 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT04290897 | Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors | completed | Phase 2 | 18 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT03953157 | Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors | completed | N/A | 9 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT05841706 | Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients Undergoing a Pancreatectomy for Pancreatic Cancer | terminated | Early Phase 1 | 1 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT02756130 | Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC) | withdrawn | Phase 1 / Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT05457959 | Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant | withdrawn | Phase 1 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT02176902 | Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer | active not recruiting | N/A | 107 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT03546361 | CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer | active not recruiting | Phase 1 | 24 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT04375527 | Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma | terminated | Phase 2 | 3 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT03732352 | 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma | completed | Phase 2 | 12 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT01149850 | Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma | completed | Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT01204684 | Dendritic Cell Vaccine for Patients With Brain Tumors | completed | Phase 2 | 24 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT03892720 | Stereotactic Body Radiation Therapy Using HyperArc in Treating Patients With Recurrent Head and Neck Cancer | completed | N/A | 33 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT03970252 | Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer | completed | Early Phase 1 | 28 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT01873248 | Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective | completed | Early Phase 1 | 100 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 19, 2024 | clinicaltrials |
| NCT02830165 | Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery | completed | N/A | 11 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT01591577 | Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT05950113 | CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT06090630 | MR Correlated Spectroscopic Imaging for Diagnosing Breast Cancer | completed | Early Phase 1 | 83 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT03623854 | Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma | completed | Phase 2 | 10 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT03732950 | Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer | active not recruiting | Phase 2 | 5 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT05720988 | Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT01345136 | Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma | terminated | Phase 2 | 4 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT01624285 | Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer | completed | Phase 2 | 20 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT03618134 | Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner | terminated | Phase 1 / Phase 2 | 19 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT03904251 | CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia | terminated | Phase 1 | 13 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT03240861 | Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer(NYESO SCT) | terminated | Phase 1 | 5 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT04299620 | Micro-Ultrasound for the Detection and Localization of Prostate Cancer Tumors in Patients Undergoing Radical Prostatectomy | active not recruiting | N/A | 86 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT03825796 | CPX-351 Plus Enasidenib for Relapsed AML | active not recruiting | Phase 2 | 2 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT04185311 | Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted | terminated | Phase 1 | 6 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT04705025 | Cognitive-Behavioral Stress Management Device for the Treatment of Anxiety and Depressive Symptoms in Patients With Stage I-III Breast or Lung Cancer(BNT001) | terminated | N/A | 5 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 25, 2023 | clinicaltrials |
| NCT05000359 | A Mobile Phone Intervention to Promote Adherence to Survivorship Care Among Adolescent and Young Adult Cancer Survivors | withdrawn | Early Phase 1 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT04106362 | Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma | terminated | Phase 2 | 1 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT04603365 | Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 0 | May 17, 2023 | clinicaltrials |
| NCT02881242 | Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer | active not recruiting | Phase 2 | 14 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 1, 2023 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials